Previous close | 27.90 |
Open | 27.90 |
Bid | 24.65 |
Ask | 29.40 |
Strike | 55.00 |
Expiry date | 2025-12-19 |
Day's range | 27.90 - 27.90 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Germany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday that almost all of its expected 2024 revenues would come in at the end of the year. BioNTech, which is investing money earned during the pandemic in cancer drug development, said in a statement that it is still targeting 2024 revenues in a range of 2.5 billion euros ($2.69 billion) to 3.1 billion euros. "BioNTech expects to recognize approximately 90% of its full year revenues in the last months of 2024," the company added.
Germany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday that almost all of its expected 2024 revenues would come in at the end of the year. BioNTech said in a statement that it is still targeting 2024 revenues in a range of 2.5 billion euros ($2.69 billion) to 3.1 billion euros. "BioNTech expects to recognize approximately 90% of its full year revenues in the last months of 2024," the company added.
NEW YORK, May 06, 2024--Pfizer Inc. (NYSE: PFE) today announced that Andrew Baum, M.D., will join the company as Chief Strategy and Innovation Officer, Executive Vice President. Dr. Baum will be a member of Pfizer’s Executive Leadership Team reporting to Chairman and Chief Executive Officer, Dr. Albert Bourla. He joins Pfizer from Citi, where he served as Head of Global Healthcare, Managing Director Equity Research. Prior to joining Citi in 2011, Dr. Baum covered European Pharmaceuticals at Morg